Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022.
Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.
NextGateTech is a FinTech company targeting the asset management industry. It offers modular softwar...
Relieving pain and anxiety in patients through virtual reality, without medication
Mira Visual Creations
Mira Visual Creations is active in the visual design and decorative arts sector. A combination of pi...
VitriCell is a company aiming at providing solutions for safe and efficient cryopreservation of most...
At Botronics, we envision a future where humans are liberated from the shackles of repetitive and mu...
Ethernetics is a digital green company with one major mission: decarbonize the internet and offer a...
The startup wants to revolutionize the world of communication and marketing through magic.
In the Air
Née dans une chambre d’étudiant, In The Air acquiert rapidement une renommée internationale grâce à...
Kameo Bikes is a startup offering bike sales and leasing for businesses.
Pipaillon offers a complete range of jams, tapenades, chutneys and candied lemons.The productions ar...